About LIFT-AD

If you are interested in participating please directly contact a study site near you.

Are You or Someone You Know Living with Alzheimer's Disease? Consider Participating in the LIFT-AD Trial

LIFT-AD is a Phase 2 Study of an Investigational Drug for the Treatment of Mild to Moderate Alzheimer's Disease.

The LIFT-AD trial is evaluating if a new investigational drug (ATH-1017) is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease. ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function. ATH-1017 represents a new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline by repairing brain cells and rebuilding brain networks.

LIFT_Grandfather_Grandson

You or someone you know may be eligible if you:

  • Are between 55 and 85 years of age
  • Have been diagnosed with Alzheimer’s disease
  • Have a reliable support person or caregiver who is willing to participate in study visits, report on daily activities and oversee or help you with taking ATH-1017

Additional info:

  • Study participation and study drug are free to all participants enrolled in the study
  • You may receive a stipend to compensate for time and effort for study participation including meals, travel, etc.

* The safety and efficacy of ATH-1017 for the treatment of mild to moderate Alzheimer’s has not been previously established. Talk to your doctor about participating in Athira’s clinical trials of ATH-1017.